Seroprevalence and Associated Factors of Hepatitis B and C Virus Among Pulmonary Tuberculosis Patients Attending Health Facilities in Gondar Town, Northwest Ethiopia

References

• AyeleAG, Gebre-SelassieS. Prevalence and risk factors of hepatitis B and hepatitis C virus infections among patients with chronic liver diseases in public hospitals in Addis Ababa, Ethiopia. ISRN Trop Med. 2013;2013:1–7. doi:10.1155/2013/56382125285308
   PubMedGoogle Scholar
• LemoineM, EholiéS, LacombeK. Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach. J Hepatol. 2015;62(2):469–476. doi:10.1016/j.jhep.2014.10.00825457207
   PubMed Web of Science ®Google Scholar
• RyanKJ, RayCG, SherrisJC. Sherris Medical Microbiology: An Introduction to Infectious Diseases. New York: McGraw-Hill; 2004.
   Google Scholar
• PommervilleJC, AlcamoIE. Alcamo’s Fundamentals of Microbiology. Sudbury, Mass.: Jones and Bartlett; 2011.
   Google Scholar
• HarveyRA. Microbiology. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007.
   Google Scholar
• KayserFH. Medical microbiology. Stuttgart; New York, NY: Georg Thieme Verlag; 2005.
   Google Scholar
• CarterJB, SaundersVA. Virology: Principles and Applications. Chichester, England; Hoboken, NJ: John Wiley & Sons; 2007:358.
   Google Scholar
• StanawayJD, FlaxmanAD, NaghaviM, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–1088. doi:10.1016/S0140-6736(16)30579-727394647
   PubMed Web of Science ®Google Scholar
• HajarizadehB, Razavi-ShearerD, MeratS, AlavianSM, MalekzadehR, RazaviH. Liver disease burden of hepatitis C virus infection in Iran and the potential impact of various treatment strategies on the disease burden. Hepat Mon. 2016;16(7):e15641. doi:10.5812/hepatmon.37234
   Web of Science ®Google Scholar
• ChhatwalJ, WangX, AyerT, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology. 2016;64(5):1442–1450. doi:10.1002/hep.2857127015107
   PubMed Web of Science ®Google Scholar
• WedemeyerH, DoreGJ, WardJW. Estimates on HCV disease burden worldwide - filling the gaps. J Viral Hepat. 2015;22:1–5. doi:10.1111/jvh.12371
   PubMed Web of Science ®Google Scholar
• YounossiZ, BrownA, ButiM, et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. J Viral Hepat. 2016;23(3):217–226. doi:10.1111/jvh.1248326482680
   PubMed Web of Science ®Google Scholar
• YounossiZ, ParkH, HenryL, AdeyemiA, StepanovaM. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150(7):1599–1608. doi:10.1053/j.gastro.2016.02.03926924097
   PubMed Web of Science ®Google Scholar
• Organisation mondiale de la santé, editor. Global Tuberculosis Report 2017. Geneva: World health organization; 2017.
   Google Scholar
• SilvaDR, Muñoz-TorricoM, DuarteR, et al. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. J Bras Pneumol. 2018;44(2):145–152. doi:10.1590/s1806-3756201700000044329791552
   PubMed Web of Science ®Google Scholar
• BrooksGF. Jawetz, Melnick & Adelberg’s Medical Microbiology. New York; London: McGraw-Hill Medical; 2007.
   Google Scholar
• SharifzadehM, RasoulinejadM, ValipourF, NouraieM, VaziriS. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberclosis treatment. Pharmacol Res. 2005;51(4):353–358. doi:10.1016/j.phrs.2004.10.00915683749
   PubMed Web of Science ®Google Scholar
• BlumbergHM, BurmanWJ, ChaissonRE, DaleyCL. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603–662.12588714
   PubMed Web of Science ®Google Scholar
• AiresR, MatosM, LopesC, et al. Prevalence of hepatitis B virus infection among tuberculosis patients with or without HIV in Goiânia City, Brazil. J Clin Virol. 2012;54(4):327–331. doi:10.1016/j.jcv.2012.04.00622608842
   PubMed Web of Science ®Google Scholar
• AbdallahTM, IdrissMI, AhmedAM, Ali-A-A-A, SaeedOK. Sero-prevalence of hepatitis B and hepatitis C viruses among tuberculosis patients in Kassala, Eastern Sudan. Glob J Infect Dis Clin Res. 2015;1(1):1–3. doi:10.17352/2455-5363.000001
   Google Scholar
• KhaliliH, DashtiKS, RasoulinezhadM, RezaeiL, EtminaniM. Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome; 2009.
   Google Scholar
• WoldegiorgisAE, ErkuW, MedhinG, BerheN, LegesseM. Community-based sero-prevalence of hepatitis B and C infections in South Omo Zone, Southern Ethiopia. PLoS One. 2019;14(12):e0226890. doi:10.1371/journal.pone.022689031887192
   PubMed Web of Science ®Google Scholar
• AberaB, AdemY, YimerM, MuluW, ZenebeY, MekonnenZ. Community seroprevalence of hepatitis B, C and human immunodeficiency virus in adult population in gojjam zones, northwest Ethiopia. Virol J. 2017;14(1):1–5. doi:10.1186/s12985-017-0696-628081705
   PubMed Web of Science ®Google Scholar
• AbebeA, NokesD, DejeneA, EnquselassieF, MesseleT, CuttsF. Seroepidemiology of hepatitis B virus in Addis Ababa, Ethiopia: transmission patterns and vaccine control. Epidemiol Infect. 2003;131(1):757–770. doi:10.1017/S095026880300857412948377
   PubMed Web of Science ®Google Scholar
• KimWS, LeeSS, LeeCM, et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis. 2016;16(1):50. doi:10.1186/s12879-016-1344-226833347
   PubMed Web of Science ®Google Scholar
• Fernández-VillarA, SopeñaB, Fernández-VillarJ, et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2004;8(12):1499–1505.15636498
   PubMed Web of Science ®Google Scholar
• ChenL, BaoD, GuL, et al. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis. 2018;18(1):1–10. doi:10.1186/s12879-018-3192-829291713
   PubMed Web of Science ®Google Scholar
• WuP-H, LinY-T, HsiehK-P, ChuangH-Y, Sheu-C-C. Hepatitis C virus infection is associated with an increased risk of active tuberculosis disease: a nationwide population-based study. Medicine. 2015;94(33):e1328. doi:10.1097/MD.000000000000132826287416
   PubMed Web of Science ®Google Scholar
• Population Census Commission. Summary and statistical report of the 2007 population and housing census. Population size by age and sex; 2008.
   Google Scholar
• NailAM, AhmedNE, GaddourMO. Seroprevalence of hepatitis B and C viruses among tuberculosis patients. Sudan J Med Sci. 2013;8(1):17–22.
   Google Scholar
• FissehatsionK, AliI, GetachewA. Seroprevalence and risk factors of sexually transmitted infections (HIV, HBV and syphilis) among pregnant women provided health care services, Addis Ababa, Ethiopia. Am J Health Res. 2017;5(5):154–161.
   Google Scholar
• Beijing Wantai Biological Pharmacy Enterprise Co. L. Diagnostic kit for hepatitis B virus Surface Antigen (ELISA); 2021. Available from: https://www.ystwt.cn/wp-content/uploads/2018/04/Wantai-HBsAg-ELISA.pdf. Accessed 826, 2021.
   Google Scholar
• Ethiopia Federal Minister of Health. Guidelines for Clinical and Programmatic Management of TB, Leprosy and TB/HIV in Ethiopia. 6th ed. Ethiopia Federal Minister of Health; 2018.
   Google Scholar
• World Health Organization. Xpert MTB/RIF Implementation manual: technical and operational ‘How-To’; Practical considerations. World Health Organization; 2014. Report No.: 9241506709.
   Google Scholar
• Federal Democratic Republic of Ethiopia Ministry of Health/ Ethiopian Public Heath Institute. Implementation Guideline for GeneXpert MTB/RIF Assay in Ethiopia. Federal Democratic Republic of Ethiopia Ministry of Health/ Ethiopian Public Heath Institute; 2014.
   Google Scholar
• Federal Democratic Republic of Ethiopia Ministry of Health. National Guidelines for TB, Drug Resistant TB and Leprosy in Ethiopia. 6th ed. Federal Democratic Republic of Ethiopia Ministry of Health; 2017.
   Google Scholar
• JasmerRM, SeamanCB, GonzalezLC, KawamuraLM, OsmondDH, DaleyCL. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med. 2004;170(5):561–566. doi:10.1164/rccm.200401-095OC15184210
   PubMed Web of Science ®Google Scholar
• LomtadzeN, KupreishviliL, SalakaiaA, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS One. 2013;8(12):e83892. doi:10.1371/journal.pone.008389224367617
   PubMed Web of Science ®Google Scholar
• AghaMA, El-MahalawyII, SeleemHM, HelwaMA. Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity. Egypt J Chest Dis Tubercul. 2015;64(1):91–96. doi:10.1016/j.ejcdt.2014.09.009
   Google Scholar
• MoP, ZhuQ, TeterC, et al. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Int J Infect Dis. 2014;28:95–100. doi:10.1016/j.ijid.2014.06.02025218771
   PubMed Web of Science ®Google Scholar
• BushnellG, StennisN, DrobnikA, et al. Characteristics and TB treatment outcomes in TB patients with viral hepatitis, New York City, 2000–2010. Epidemiol Infect. 2015;143(9):1972–1981. doi:10.1017/S095026881400297025387450
   PubMed Web of Science ®Google Scholar
• FrancoE, BagnatoB, MarinoMG, MeleleoC, SerinoL, ZarattiL. Hepatitis B: epidemiology and prevention in developing countries. World J Hepatol. 2012;4(3):74. doi:10.4254/wjh.v4.i3.7422489259
   PubMedGoogle Scholar
• NooredinvandHA, ConnellDW, AsgheddiM, et al. Viral hepatitis prevalence in patients with active and latent tuberculosis. World J Gastroenterol. 2015;21(29):8920. doi:10.3748/wjg.v21.i29.892026269682
   PubMed Web of Science ®Google Scholar
• AkhtarJAJ, Qamar MuSa, AnwarJ. Sero-prevalence of HBV and HCV in tuberculosis patients at Sheikh Zayed hospital Rahim Yar khan, Pakistan. Biomedica. 2013;29(2):69–72.
   Google Scholar
• MerzaMA, HajiSM, AlsharafaniAMH, MuhammedSU. Low prevalence of hepatitis B and C among tuberculosis patients in Duhok Province, Kurdistan: are HBsAg and anti-HCV prerequisite screening parameters in tuberculosis control program?Int J Mycobacteriol. 2016;5(3):313–317. doi:10.1016/j.ijmyco.2016.06.01927847016
   PubMedGoogle Scholar
• MartinNK, VickermanP, KhakooS, et al. Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation. BMJ Open. 2019;9(6):e030183. doi:10.1136/bmjopen-2019-030183
   Web of Science ®Google Scholar
• Health Protection Agency Centre for Infections. Tuberculosis in the UK: Annual Report on Tuberculosis Surveillance in the UK, 2010. London: Health Protection Agency Centre for Infections; 2010.
   Google Scholar
• AliSA, DonahueRM, QureshiH, VermundSH. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int J Infect Dis. 2009;13(1):9–19. doi:10.1016/j.ijid.2008.06.01918835208
   PubMed Web of Science ®Google Scholar
• KasradzeA, KuchukhidzeG, BaliashviliD, et al. Prevalence and risk factors for hepatitis B infection in the adult population of Georgia: a nationwide survey. J Hepatol. 2017;66(1):S468–S469. doi:10.1016/S0168-8278(17)31324-7
   Web of Science ®Google Scholar
• ImoruM, BalaA, MarafaA. Prevalence rates of HIV, HBsAg and HCV co-infections among tuberculosis patients in Sokoto Metropolis, Northwest Nigeria. Sri Lankan J Infect Dis. 2018;8(2):84. doi:10.4038/sljid.v8i2.8219
   Google Scholar
• UngoJR, JonesD, AshkinD, et al. Antituberculosis drug–induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157(6):1871–1876. doi:10.1164/ajrccm.157.6.97110399620920
   PubMed Web of Science ®Google Scholar
• Pedral-SampaioDB, AlvesCR, NettoEM, BritesC, OliveiraAS, BadaroR. Efficacy and safety of efavirenz in HIV patients on rifampin for tuberculosis. Braz J Infect Dis. 2004;8:211–216. doi:10.1590/S1413-8670200400030000415476053
   PubMedGoogle Scholar
• YeeD, ValiquetteC, PelletierM, ParisienI, RocherI, MenziesD. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472–1477. doi:10.1164/rccm.200206-626OC12569078
   PubMed Web of Science ®Google Scholar